Vivos Inc (RDGL)

[DiamondFire]

ADMD's Y-90: Superior Cancer Treatment: DD

ADMD is a company that in the last decade, has developed new cancer treatments utilizing 'Y-90' brachytherapy and radioembolization biotechnology -- a biotechnology that was tested clinically in the '80's and '90's and now is becoming a preferred treatment method for a growing list of cancers. And most excitedly here with ADMD, as you will read below: they have developed comparable and from what i read even BETTER treatments using Y-90 for patients then their competitors...

....and this is a mere penny stock; the financial return could be immense - yet infinitely more important are the lives that could be both saved and helped by them: its whats its all about.

---------------

...first thing though real quick....anyone notice the Form 4 filed May 1st?:: Carlton Cadwell got over 8.8 million more shares @ .003. He is a Director and 10% owner of ADMD.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10662450

This news soon after we found out Cadwell also is rolling most of his and his estates debt into Preferred Series A shares, @ .015 cents of ADMD shares, not dilutive until company is uplisted to a national Exchange, (ie Nasdaq) --- now how could that ever happen, without FDA approval? It simply would be unheard of for the Nasdaq to want to up list an unproven and failed FDA biotech penny stock, yes? - so why would Cadwell do this and risk some $6 million if he wasnt confident ADMD will get approval?---:

http://finance.yahoo.com/news/advanced-medical-isotope-corporation-initiates-102000081.html

---Form 4's are some of the best 'insider' signs as we all know.....and if you read below you may get a glimpse as to why he not only got more shares of late -- but agreed to roll in all this debt for the long haul with ADMD. Upon FDA approval guys, ADMD's Y-90 cancer treatment would become, from what i read or i guess anyone would read and learn, one of the best and modern biotech ways for the doctors to safely - attack and kill tumors:

------------

But before we go further, we all need to do some DD, to understand whats at stake here: revolutionary new ways to treat cancers. ....and there are many links and info on Y-90: just know that it is one of the best, and newest cancer fighting biotechnologies in the modern world, as it was already clinically tested in the '80's and '90's. Here are some links that i found helpful in researching Y-90 therapies and function, for you to browse through when you have the time:

http://www.radiologyinfo.org/en/info.cfm?pg=radioembol

http://www.eurekalert.org/pub_releases/2014-03/soir-ypn031114.php

https://depts.washington.edu/uwvir/wordpress/wp-content/uploads/2012/02/Yttrium-90-Radiotherapy-Liver-Tumors.pdf

http://en.m.wikipedia.org/wiki/Selective_internal_radiation_therapy

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702899/

-----------------

BUT, today - RIGHT NOW with ADMD and their own developed Y-90 biotech advances -- with the hopeful FDA approval that we all are waiting on....if approved it would offer the world of cancer patients the below radical new Benefits(!): read what benefits (aka 'advantages') their treatments offer from the below excerpt of their 10K and then from a PR excerpt below the 10K: SEVERAL key advantages to the patients - AND to the doctors, staff and family around them too - - - but first the information from Page 4 of their last 10K:

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10628462


Based upon its studies and analyses, or general application of experience with current brachytherapy devices and yttrium-90, the Company believes that if we are able to obtain regulatory approval and adequate financing to commercialize our products, our brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:

·
Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to cancer tissues, with less radiation reaching adjacent normal tissues.

·
Half Life: The industry-standard products have a half-life of 17 days, meaning the patient is radioactive for over two months. The Company’s brachytherapy products use the yttrium-90 isotope, which has a half-life of just 2.7 days. A patient treated with Y-90 would be close to radiation free in 10 days.

·
Optimized Delivery Method: Current brachytherapy devices place permanent metal particles seeds in the prostate by using up to 30 large gauge needles. By contrast, the Company’s biodegradable polymer carrying Y-90 particles may be administered with small-gauge needles.

·
No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. The Company’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.

·
Good Safety Profile: Many current brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and the isotopes used in current brachytherapy products can remain radioactive for more than two months. The Company’s brachytherapy products use the yttrium-90 isotope, which is a beta-emitter. The yttrium-90 beta-emissions travel only a short distance and have a short half life of 2.7 days.



...and from a PR a couple years ago that explains the above very well too, as do many of the PR's since then - but i think this one best explains everything. And yes it has been a long journey (as with all new biotech company's and especially new treatments on the market) as it takes years or even decades for new treatments and therapies by biotech companies to finally hit the market. But fortunately for us here today - ADMD's FDA decision is coming up and even overdue -- and most all here have bought sub-penny shares and the big dip the last couple years...and not above .04 cents or a dime shares as in years past:


"AMIC's analyses support an expectation that its brachytherapy products will achieve a higher therapeutic index than existing brachytherapy products, while reducing collateral damage to healthy tissue due to the shorter penetration distance, shorter half-life and other attributes of the device as compared to brachytherapy devices that use isotopes emitting gamma radiation. These features also reduce the risk of radiation exposure to the patient, family members and medical personnel involved in manufacturing and injecting the device. The AMIC Y-90 RadioGel™ device uses a biodegradable carrier with FDA approved components which leaves no metal or glass in the patient.

AMIC anticipates that these features will permit it to reduce the cost of manufacturing, compared to existing brachytherapy products. AMIC intends to pass along a portion of any savings to its customers, permitting medical practice groups, hospitals, insurers and patients to share in the anticipated cost benefit.
"The value of Y-90 radioembolization in treating patients with non-operative primary liver cancer and metastatic colon cancer has been demonstrated," said Lewandowski. Given the low toxicity and high disease control rates, this therapy is expanding to other secondary hepatic malignancies, he said. "We're looking to gain maximal tumor control while minimizing toxicity and preserving quality of life," he added.....the therapy is not limited by tumor size, shape, location or number, and it can ease the severity of disease in patients who cannot be treated effectively with other approaches...

...the anticipated introduction of the Yttrium-90 products will mark AMIC's transition from a development-stage company to an operating company. AMIC CEO Jim Katzaroff commented."

http://globenewswire.com/news-release/2013/11/04/586042/10055867/en/Advanced-Medical-Isotope-Corporation-Files-510-k-Pre-Market-Notification-for-FDA-Clearance-of-Yttrium-90-RadioGel-TM-Brachytherapy-Product.html



...now below IHub Poster 'CatPuke' lol posted this yesterday that i also want to highlight....and its a must read too for anyone here invested or looking to get in...: did you know that ADMD has TWO OTHER Y-90 products that they also plan to send to the FDA for approval - with this hopeful initial approval coming up...?:


CatPuke Friday, 05/01/15 01:51:50 PM
Re: None
Post # of 25724


From the last 10K: If there is FDA approval there are two additional products they will seek clearance for...

Subject to receipt of all required regulatory approvals from the FDA in the United States and analogous regulators outside of the United States, the Company plans to introduce a new Y-90-based brachytherapy product line for a range of applications for the delivery of a prescribed dose of radiation to a target site. There can be no assurance that we will obtain such approvals. Our open FDA application is a de novo for the Y-90 RadioGel™ device. If we receive FDA clearance for the Y-90 RadioGel™ device, subject to receipt of adequate financing, we will commence commercialization of that product. Also, subject to receipt of adequate financing, we intend then to seek FDA clearance for the two additional products described below, each of which also incorporates the patented technologies licensed from Battelle. Even if the FDA grants clearance for the Y-90 RadioGel™ device there can be no assurance the FDA would also grant clearance for either or both of the foregoing products. (...here are the new Y-90 products that would ADMD would also then seek for FDA clearance with initial approval!):

Y-90 RadioGel™ device - combines Y-90 particles with a polymer carrier that may be injected directly into the tumor.

Y-90 Fast-Resorbable Polymer Seeds - Y-90 contained within a polymer seed, as opposed to metal or glass. This product would be used in place of treating cancers with currently marketed titanium or glass seeds.

Y-90 Polymer Topical Paste – designed to be applied directly to tissue surfaces after surgical tumor removals (also referred to as “resections”) to treat residual tumor cells.


http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10628462



SO: a possible trifecta-Biotech stock here guys with ADMD, as the hottest new biotech in Pennyland and maybe any under $5 biotech stock - cause with this hopeful initial approval it sets ADMD up for 2015...and beeeeyond: 3 potential new in total (with the two above to seek clearance if the first one is cleared) Y-90 cancer killing biotech products, that can better kill cancer cells and are safer for the patients and those around them: 3(!).

And this is less then a penny. Stocks with such FDA approved and revolutionary and novel biotechnologies that ADMD offers via Y-90 often trade @ $30 to $100 and more -a share-. ....do you think that biotech and other big board traders/money will be attracted to ADMD IF they get their FDA clearance.....then they realize what a step up in cancer and tumor treatment ADMD's Y-90 offers when researching the company --- then realize that with a FDA approval 2 more Y-90 therapys would then be immediately pursued by ADMD?

- i think a huge biotech spotlight will be on ADMD for awhile then, with FDA approval..... and if you have been visiting StockCharts.com, notice that recently ticker 'ADMD' has often popped up on their homepage in 'the most charted stocks' - btw usually the only penny stock...next to billion dollar giants Apple, Google, Twitter, FB etc.....to me it says yeah people are starting to notice ticker ADMD across the Financial Boards. Now this changes often on StockCharts homepage as its constantly updated - but its cool to see ANY penny stock make this page even once a week when contemplated, being how much smaller the Penny Market is then say the the Naz...Apples Net Revenues alone may be more then what the entire penny market trades dollar wise for a year lol:

http://stockcharts.com



ADMD is the Penny Stock Markets 2015 FDA approval play: and nothing runs, or attracts big money, quite like FDA approval stocks. So consider a position out there, cause w hopeful approval look for not only the obvious initial pps spike, but look for the Accumulation here to continue: as ADMD would then be of a select number of biotech companies allowed by the FDA to market and treat patients with their own modern-day and proprietary Y-90 cancer treatments -- with two new Y-90 treatments planned to come after and in time to also be pursued and marketed.

Or if your really skittish - just sit on da' sidelines and wait for the final Yes or No FDA decision, and only invest what money you can completely afford to lose Oh My Hobbits!........i know ive been there, and went from an Elf to a broke Orc digging mines in Mordor, lol

ADMD: the biggest Penny Stock FDA play in years....